Contrast developer Bracco Diagnostics has received Food and Drug Administration clearance for its MultiHance gadolinium-based MR contrast agent.
MultiHance is indicated for use in MRI of the central nervous system in adults to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues, according to Bracco of Princeton, NJ. Bracco said MultiHance demonstrates a strong increase in relaxivity in any solution containing serum proteins, which provides for greater signal intensity enhancement.
By AuntMinnie.com staff writers
November 24, 2004
Related Reading
SonoVue reinstated for echo use, November 1, 2004
Berlex, Bracco, E-Z-EM, PETNet form consortium, September 27, 2004
CHMP recommends SonoVue reinstatement, August 5, 2004
Bracco clarifies SonoVue restrictions, May 24, 2004
EMEA restricts use of SonoVue, May 20, 2004
Copyright © 2004 AuntMinnie.com
